Clinical trial

A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects

NCT01221259

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2010-01-01

PhasePHASE1

Study timeline

Study start (unknown)2010-01-01Date precision: month

Registry last updated2013-05-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Alzheimer's Diseaseunresolved

Interventions

E2212DRUG

placeboDRUG

Sponsors & collaborators

Eisai Inc.lead sponsor

Mapped research locations

Overland ParkKansas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01221259 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.